The Journal of Alzheimer's Disease (AD) has devoted its entire March issue to the study of the use of biomarkers in the treatment of Alzheimer's disease.
The journal's publisher, the IOS Press, claims that specific biomarkers are required to allow different types of cognitive impairment to be diagnosed.
In addition, the use of biomarkers will allow doctors to better monitor and treat the different forms of dementia, it states.
Elaine R Peskind and Thomas J Montine of the University of Washington write in the journal's foreword: "Progress toward controlling if not eradicating AD is at a crossroads where clinical, pathological and basic science studies have identified therapeutic targets that are now being tested.
"Critical to translating this knowledge to improved patient care will be developing panels of biomarkers that complement the clinical exam, cognitive testing, and neuroimaging."
Experts state that unlike other age related illnesses such as diabetes mellitus, hypercholesterolemia and hypertension, biomarker tests can easily be implemented on Alzheimer's sufferers.